Preprint · OA
via OpenAlex
Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status
CNS Drugs · 2013 · ▲ 53 citations
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s40263-013-0055-0
- Canonical
- link ↗
- Fetched
- 2026-10-23 MST
Cite this
APA
Duan, W. (2013). Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status. <em>CNS Drugs</em>. https://doi.org/10.1007/s40263-013-0055-0
Vancouver
Duan W. Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status. CNS Drugs. 2013. doi:10.1007/s40263-013-0055-0.
BibTeX
@unpublished{wenzhen2013Target,
title = {Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status},
author = {Wenzhen Duan},
journal = {CNS Drugs},
year = {2013},
doi = {10.1007/s40263-013-0055-0},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
PubMed 1989
Preprint
Alzheimer's disease: current and emerging topics on age-related neurodegeneration.
Zeitschrift für Gerontologie und Geriatrie 2024
Open access · OA
Geroscience: Möglichkeiten und Herausforderungen für das Gesundheitswesen und die Gesellschaft der Zukunft
Gastroenterology 2014
Open access · OA
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Nature Cell Biology 2024
Preprint · OA
Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington’s disease
Annals of Clinical and Translational Neurology 2014
Open access · CC-BY
Sirtuin 1 activator SRT 2104 protects Huntington's disease mice
Nature Reviews Cardiology 2017
Preprint · OA